Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 5:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 13,769 matching trials from the live ClinicalTrials.gov search.
Filters: Dallas, Texas Clear all
Completed Phase 3 Interventional Results available

A Study of PTC923 in Participants With Phenylketonuria

NCT05099640
View directory record Official record
Conditions
Phenylketonuria
Interventions
PTC923, Placebo
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Stanford, California • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 2 Interventional

A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis

NCT00303563
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
P38 Inhibitor (4), Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
22
States / cities
Anniston, Alabama • Scottsdale, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 4, 2026, 5:01 PM EST
Completed No phase listed Observational

A Study to Examine Levels of Sedation During Outpatient Colonoscopies

NCT00614263
View directory record Official record
Conditions
Outpatient Colonoscopy
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2017 · Synced Nov 4, 2026, 5:01 PM EST
Active, not recruiting Phase 2 Interventional

Domvanalimab and Zimberelimab in Advanced Liver Cancers

NCT05724563
View directory record Official record
Conditions
Hepatobiliary Cancer, Liver Cancer, Cholangiocarcinoma, Hepatocellular Carcinoma
Interventions
Zimberelimab, Domvanalimab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 3 Interventional Results available

Dysport® Adult Upper Limb Spasticity

NCT01313299
View directory record Official record
Conditions
Nervous System Disorders
Interventions
Botulinum toxin type A, Placebo
Biological · Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 80 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
15
States / cities
Downey, California • Fairfield, Connecticut • Boca Raton, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Nov 4, 2026, 5:01 PM EST
Active, not recruiting Phase 2 Interventional

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

NCT05849298
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
AAA617, AAA517, Piflufolastat F 18, ARPI, ADT, Best supportive care
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
10
States / cities
Denver, Colorado • Athens, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Active, not recruiting Phase 3 Interventional

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

NCT07288398
View directory record Official record
Conditions
Pulmonary Hypertension Associated With HFpEF
Interventions
TNX-103, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
45
States / cities
Alexander City, Alabama • Tucson, Arizona • Sacramento, California + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 3 Interventional Results available

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

NCT02627963
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Tivozanib hydrochloride, Sorafenib
Drug
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
56
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Nov 4, 2026, 5:01 PM EST
Active, not recruiting Not applicable Interventional

WATER IV Prostate Cancer

NCT06651632
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
Aquablation Therapy, Radical Prostatectomy
Device · Procedure
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years and older · Male only
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
26
States / cities
Chandler, Arizona • Mesa, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Nov 4, 2026, 5:01 PM EST
Enrolling by invitation Phase 3 Interventional

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT04905693
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Interventions
Inhaled Treprostinil, Treprostinil Ultrasonic Nebulizer
Drug · Device
Lead sponsor
United Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
1,850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
81
States / cities
Birmingham, Alabama • Franklin, Arizona • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 2 Interventional Results available

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

NCT02582684
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Dolutegravir, Lamivudine
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
25
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

NCT03242252
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease Stage 3
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
51
States / cities
Birmingham, Alabama • Guntersville, Alabama • Phoenix, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 2 Interventional

A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001)

NCT03594058
View directory record Official record
Conditions
Overactive Bladder
Interventions
Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo
Drug
Lead sponsor
Velicept Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years · Female only
Enrollment
1,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Guntersville, Alabama • Saraland, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 3 Interventional

Laparoscopic Adjustable Gastric Banding Versus Laparoscopic Sleeve Gastrectomy

NCT00434655
View directory record Official record
Conditions
Morbid Obesity
Interventions
Laparoscopic restrictive procedure
Procedure
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2009 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 3 Interventional Results available

Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range

NCT05564117
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Semaglutide, Placebo semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
7
States / cities
Birmingham, Alabama • Costa Mesa, California • Honolulu, Hawaii + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Completed Not applicable Interventional Results available

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

NCT03123250
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Aquablation
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
45 Years to 80 Years · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
13
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Nov 4, 2026, 5:01 PM EST
Active, not recruiting Not applicable Interventional

Cycled Phototherapy

NCT03927833
View directory record Official record
Conditions
Hyper Bilirubinemia, Premature Infant
Interventions
Phototherapy lights
Device
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
22 Weeks to 27 Weeks
Enrollment
1,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Active, not recruiting Phase 2 Interventional Results available

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

NCT02275533
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Clinical Observation, Echocardiography Test, Nivolumab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
45
States / cities
Birmingham, Alabama • Tucson, Arizona • Duarte, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 4, 2026, 5:01 PM EST
Terminated Phase 3 Interventional

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

NCT00937352
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bapineuzumab
Drug
Lead sponsor
JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Industry
Eligibility
51 Years and older
Enrollment
896 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
176
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 140 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2013 · Synced Nov 4, 2026, 5:01 PM EST
Recruiting Phase 1 Interventional

Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis

NCT06982352
View directory record Official record
Conditions
Atopic Dermatitis (AD), Psoriasis (PsO)
Interventions
LPX-TI641, Placebo
Drug
Lead sponsor
LAPIX Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Fargo, North Dakota • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 2 Interventional

A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL)

NCT00611208
View directory record Official record
Conditions
T-cell Lymphomas, T-cell Leukemia, Sezary Syndrome, Mycosis Fungoides, Cutaneous T-cell Lymphoma (CTCL)
Interventions
A-dmDT390-bisFv(UCHT1)
Biological
Lead sponsor
Virogen Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
New Haven, Connecticut • Louisville, Kentucky • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 4 Interventional Results available

Effect of Dapagliflozin on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled With Either Metformin Or Insulin

NCT02429258
View directory record Official record
Conditions
Type II Diabetes
Interventions
Farxiga, Placebo, Metformin, Insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Park, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Nov 4, 2026, 5:01 PM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448
View directory record Official record
Conditions
Pneumococcal Infections, Pneumococcal Vaccines
Interventions
V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Nov 4, 2026, 5:01 PM EST